AFAlison Finnegan

Alison Finnegan

*This is an algorithmically generated author record based on publicly available information.

Alison Finnegan has a total of 50 co-authors. Here are the top co-authors by number of shared publications:

  • Yanxia Cao

    †Department of Internal Medicine, Division of Rheumatology, Rush University Medical Center, Cohn Research Building, Chicago, IL, USA

    11 shared publications
  • Keith M. Hamel

    §Department of Medicine, Section of Rheumatology, Gwen Knapp Center for Lupus and Immunology Research, The University of Chicago, IL, USA

    9 shared publications
  • Yumei Wang

    †Department of Internal Medicine, Section of Rheumatology, Rush University Medical Center, Cohn Research Building, Chicago, IL 60612

    6 shared publications
  • Katalin Mikecz

    Rush University Medical Center, Chicago, Illinois

    4 shared publications
  • Paul D. Doodes

    Department of Immunology/Microbiology, Rush University Medical Center, Chicago, IL 60612, USA

    4 shared publications
  • Tibor T. Glant

    ‡Department of Internal Medicine, Section of Rheumatology, Rush University Medical Center, Cohn Research Building, Chicago, IL 60612

    4 shared publications

Latest Publications

  • Open Access

    B cells expressing IFN‐γ suppress Treg‐cell differentiation and promote autoimmune experimental arthritis

    by Susan A. Olalekan, Yanxia Cao, Keith M. Hamel, Alison Finnegan

    Clinical efficacy in the treatment of rheumatoid arthritis with anti‐CD20 (Rituximab)‐mediated B‐cell depletion has garnered interest in the mechanisms by which B cells contribute to autoimmunity. We have reported that B‐cell depletion in a murine model of proteoglycan‐induced arthritis (PGIA) leads to an increase in Treg cells that correlate with decreased autoreactivity. Here, we demonstrate that the increase in Treg cells after B‐cell depletion is due to an increase in the differentiation of naïve CD4+ T cells into Treg cells. Since the development of PGIA is dependent on IFN‐γ and B cells are reported to produce IFN‐γ, we hypothesized that B‐cell‐specific IFN‐γ plays a role in the development of PGIA. Accordingly, mice with B‐cell‐specific IFN‐γ deficiency were as resistant to the induction of PGIA as mice that were completely IFN‐γ deficient. Importantly, despite a normal frequency of IFN‐γ‐producing CD4+ T cells, B‐cell‐specific IFN‐γ‐deficient mice exhibited a higher percentage of Treg cells compared with that in WT mice. These data indicate that B‐cell IFN‐γ production inhibits Treg‐cell differentiation and exacerbates arthritis. Thus, we have established that IFN‐γ, specifically derived from B cells, uniquely contributes to the pathogenesis of autoimmunity through prevention of immunoregulatory mechanisms.


  • Open Access

    Tissue specific CD4+ T cell priming determines the requirement for interleukin-23 in experimental arthritis

    by Susan A Olalekan, Yanxia Cao, Alison Finnegan

    Rheumatoid arthritis (RA) is a chronic inflammatory disease with striking heterogeneity in (i) clinical presentation, (ii) autoantibody profiles and (iii) responses to treatment suggesting that distinct molecular mechanisms may underlie the disease process. Proteoglycan-induced arthritis (PGIA) is induced by two pathways either by intraperitoneal (i.p.) or subcutaneous (s.c.) exposure to PG. CD4+ T cells primed by the i.p. route are T helper (Th)1 cells expressing interferon gamma (IFN-γ) whereas CD4+ T cells primed by the s.c. route are Th17 cells expressing interleukin (IL)-17. IL-23 is necessary for maintaining the phenotype of Th17 cells; however, IL-23 is inflammatory independent of IL-17. The aim of this study was to determine if PGIA induced by different routes of immunization is dependent on IL-23. BALB/c wild type (WT), IL-12p40−/− and IL-23p19−/− littermate mice were immunized with recombinant G1 (rG1) domain of human PG in adjuvant either i.p. or s.c. and development of arthritis monitored. Joint histology was assessed. CD4+ T cell cytokines in spleen, lymph node (LN), and joint were assessed by intracellular staining and cytokine enzyme-linked immunosorbent assay. RNA transcripts for cytokines and transcription factors were examined. PGIA was suppressed in the p40−/− and p19−/− mice immunized by the s.c. route but only inhibited in p40−/− mice by the i.p. route. The joints of s.c. but not i.p. sensitized mice contained a population of CD4+ T cells expressing single positive IFN-γ and IL-17 and double positive IFN-γ/IL-17 which were dependent on IL-23 expression. The IFN-γ and IL-17 response in spleen and inguinal LN was inhibited in p19−/− mice and p40−/− mice after s.c. immunization, whereas in i.p. immunized p19−/− mice, IL-17 but not IFN-γ was reduced. Inguinal LN CD11c+ dendritic cells (DC) from s.c. immunized, but not spleen DC from i.p. immunized mice, produced IL-23, IL-1β, and IL-6 and activated T cells to produce IL-17. IL-23 is necessary for the activity of Th17 after s.c. immunization and does not play a role independent of IL-17 after i.p. immunization. These data demonstrate that the molecular pathways IL-23/17 and IL-12/IFN-γ may represent subtypes of arthritis determined by the mode of induction.


  • Open Access

    B Cell–Specific Expression of Inducible Costimulator Ligand Is Necessary for the Induction of Arthritis in Mice

    by Keith M. Hamel, Yanxia Cao, Susan A. Olalekan, Alison Finnegan

    Objective: Inducible costimulator (ICOS)–ICOSL interactions are necessary for activation of Teff cells and follicular helper T (Tfh) cells. ICOSL is expressed on B cells, macrophages, and dendritic cells and can be induced on nonhematopoietic cells. The aim of this study was to determine whether expression of ICOSL on B cells is necessary for the development of proteoglycan (PG)–induced arthritis (PGIA).Methods: PGIA was initiated by immunizing wild‐type and ICOSL‐deficient (ICOSL−/−) or B cell–specific ICOSL−/− chimeric BALB/c mice with human PG in adjuvant. The onset and severity of arthritis were monitored over time. CD4+ T cell proliferation and CD4+ T cell cytokine production were measured in vitro after the cells were restimulated with PG. Germinal center (GC) B cells, plasma cells, Tfh cells, and Treg cells were identified by staining with specific antibodies.Results: Arthritis progression was completely inhibited in both ICOSL−/− mice and B cell–specific ICOSL−/− chimeric mice. Production of the Teff cell–produced cytokines interferon‐γ and interleukin‐17 (IL‐17) and the antiinflammatory cytokine IL‐4 was suppressed. The reduced percentages of GCs and Tfh cells and the decreased production of IL‐21 correlated with a decrease in the anti‐mouse PG antibody response. However, the percentage of plasma cells was not reduced despite a reduction in IgG responses.Conclusion: These data indicate that the signals provided by ICOSL‐expressing B cells to Teff cells and Tfh cells are necessary for the development of arthritis. Thus, therapeutic blockade of ICOSL−ICOS interactions may be an effective strategy for the treatment of rheumatoid arthritis.


  • Location of CD4+ T Cell Priming Regulates the Differentiation of Th1 and Th17 Cells and Their Contribution to Arthritis

    by Rachel Rodeghero, Yanxia Cao, Susan A Olalekan, Yoichiro Iwakua, Tibor T. Glant, Alison Finnegan

    Th cytokines IFN-γ and IL-17 are linked to the development of autoimmune disease. In models of rheumatoid arthritis, that is, proteoglycan (PG)-induced arthritis, IFN-γ is required, whereas in collagen-induced arthritis, IL-17 is necessary for development of arthritis. In this study we show that the route of immunization determines the requirement for either IFN-γ or IL-17 in arthritis. Intraperitoneal immunization with PG induces a CD4+ T cell IFN-γ response with little IL-17 in the spleen and peripheral lymph nodes. However, s.c. immunization induces both an IFN-γ and an IL-17 CD4+ T cell response in spleen and lymph nodes. The failure to induce a CD4+ T cell IL-17 response after i.p. immunization is associated with T cell priming, as naive T cells activated in vitro were fully capable of producing IL-17. Moreover, PG-induced arthritis is converted from an IFN-γ to an IL-17–mediated disease by altering the route of immunization from i.p. to s.c. The histological appearance of joint inflammation (cellular inflammation and bone erosion) is similar in the i.p. versus s.c. immunized mice despite the presence of CD4+ T cells producing IL-17 in joint tissues only after s.c. immunization. These data indicate a critical role for the site of initial T cell priming and the Th cytokines required for susceptibility to arthritis. Our findings suggest that T cell activation at different anatomical sites in rheumatoid arthritis patients may skew the T cells toward production of either IFN-γ or IL-17.


  • B effector cells in rheumatoid arthritis and experimental arthritis

    by Alison Finnegan, Susan Ashaye, Keith M. Hamel

    Rheumatoid arthritis is a chronic autoimmune immune disease affecting approximately 1% of the population. There has been a renewed interest in the role of B cells in rheumatoid arthritis based on the evidence that B cell depletion therapy is effective in the treatment of disease. This review summarizes the current knowledge of the mechanisms by which B cells contribute to autoimmune arthritis including roles as autoantibody producing cells, antigen-presenting cells, cytokine producing cells, and regulatory cells.


  • B Cell Depletion Enhances T Regulatory Cell Activity Essential in the Suppression of Arthritis

    by Keith M. Hamel, Yanxia Cao, Susan Ashaye, Yumei Wang, Robert Dunn, Marilyn R. Kehry, Tibor T. Glant, Alison Finnegan

    The efficacy of B cell-depletion therapy in rheumatoid arthritis has driven interest in understanding the mechanism. Because the decrease in autoantibodies in rheumatoid arthritis does not necessarily correlate with clinical outcome, other mechanisms may be operative. We previously reported that in proteoglycan-induced arthritis (PGIA), B cell-depletion inhibits autoreactive T cell responses. Recent studies in B cell-depletion therapy also indicate a role for B cells in suppressing regulatory mechanisms. In this study, we demonstrate that B cells inhibited both the expansion and function of T regulatory (Treg) cells in PGIA. Using an anti-CD20 mAb, we depleted B cells from mice with PGIA and assessed the Treg cell population. Compared to control Ab-treated mice, Treg cell percentages were elevated in B cell-depleted mice, with a higher proportion of CD4+ T cells expressing Foxp3 and CD25. On a per-cell basis, CD4+CD25+ cells from B cell-depleted mice expressed increased amounts of Foxp3 and were significantly more suppressive than those from control Ab-treated mice. The depletion of Treg cells with an anti-CD25 mAb concurrent with B cell-depletion therapy restored the severity of PGIA to levels equal to untreated mice. Although titers of autoantibodies did not recover to untreated levels, CD4+ T cell recall responses to the immunizing Ag returned as measured by T cell proliferation and cytokine production. Thus, B cells have the capacity to regulate inflammatory responses by enhancing effector T cells along with suppressing Treg cells.


  • Open Access

    Cover Picture: Eur. J. Immunol. 11/10

    by Keith M. Hamel, Yanxia Cao, Yumei Wang, Rachel Rodeghero, Tamas Kobezda, Lieping Chen, Alison Finnegan

    The cover image of this issue consists of an hematoxylin and eosin staining of a sagittal section of hind paw harvested from a wild‐type BALB/c mouse 6 weeks after proteoglycan (PG)‐dimethyldioctadecyl‐ammonium bromide (DDA) immunization, and is taken from Hamel et al. (pp. 3117–3127). In this article, the authors examine the role of the programmed death (PD)‐1 ligand, B7‐H1, in the development of PG‐induced arthritis (PGIA). The authors show that B7‐H1−/− mice exhibit exacerbated PGIA and increased Th1 CD4+ T‐cell responses, while the PG‐specific antibody response in these mice is diminished.

  • Open Access

    B7‐H1 expression on non‐B and non‐T cells promotes distinct effects on T‐ and B‐cell responses in autoimmune arthritis

    by Keith M. Hamel, Yanxia Cao, Yumei Wang, Rachel Rodeghero, Tamas Kobezda, Lieping Chen, Alison Finnegan

    The immune system has developed several regulatory mechanisms to maintain homeostasis of adaptive immune responses. T‐cell programmed death (PD)‐1 recognition of B7‐H1 (PD‐L1) expressed on APC and non‐lymphoid tissue regulates T‐cell activation. We show that B7‐H1−/− mice exhibit exacerbated proteoglycan (PG)‐induced arthritis and increased Th‐1 CD4+ T‐cell responses. Unexpectedly, the PG‐specific antibody response in B7‐H1−/− mice was diminished. A reduction in the number of peanut agglutinin+ GC coincided with a decrease in CD19+ GL‐7+ CD95+ GC B cells that was a result of increased caspase‐induced apoptosis. The percent of CD38+ CD138+ emerging plasma cells was decreased. B7‐H1−/− mice exhibited an increased frequency of CD4+ PD‐1hi CXCR5hi ICOShi CD62Llo T follicular helper cells that displayed a hyperactive phenotype with increased expression of mRNA transcripts for Bcl6, IL‐21, and the apoptosis‐inducer molecule FasL. In cell transfer of B7‐H1−/− cells into SCID mice, non‐B and non‐T cells were sufficient to normalize the antibody response, T‐cell hyperactivity, and the development of PG‐induced arthritis. These findings indicate that B7‐H1 on non‐B and non‐T cells signals through PD‐1 on T effector cells to prevent excessive activation and reduce autoimmune arthritis. Furthermore, these findings demonstrate a novel role for B7‐H1 expression in promoting B‐cell survival by regulating the activation of T follicular helper cell.


  • IFN-γ Regulates the Requirement for IL-17 in Proteoglycan-Induced Arthritis

    by Paul D. Doodes, Yanxia Cao, Keith M. Hamel, Yumei Wang, Rachel L. Rodeghero, Katalin Mikecz, Tibor T. Glant, Yoichiro Iwakura, Alison Finnegan

    The contribution of the proinflammatory cytokines IFN-γ and IL-17 to the pathogenesis of experimental arthritis is controversial. In proteoglycan (PG)-induced arthritis (PGIA), severe arthritis is dependent on the production of IFN-γ, whereas IL-17 is dispensable. In collagen-induced arthritis and Ag-induced arthritis, although high levels of IFN-γ are secreted, disease is exacerbated in IFN-γ or IFN-γ receptor-deficient mice due to the ability of IFN-γ to suppress IL-17 expression. In the current study, we investigated the effect of IFN-γ on the IL-17 response and its consequences in PGIA. In PG-immunized IFN-γ−/− mice, despite reduction in arthritis, the PG-specific CD4+ T cell IL-17 response was significantly increased. Elevated IL-17 contributed to development of arthritis, as disease in IFN-γ/IL-17−/− was significantly reduced in comparison with either IFN-γ−/− or IL-17−/− mice. A contribution of IFN-γ and IL-17 to the development of arthritis was also identified in T-bet−/− mice. PG-specific CD4+ T cells from T-bet−/− mice produced reduced IFN-γ and elevated concentrations of IL-17. Both IFN-γ and IL-17 contribute to arthritis, as T-bet−/− mice lacking IL-17 (T-bet/IL-17−/−) were resistant, whereas wild-type, T-bet−/−, and IL-17−/− mice were susceptible to PGIA. T cell proliferation and autoantibody production did not correlate with development of disease; however, expression of cytokines and chemokines in joint tissues demonstrate that IFN-γ and IL-17 cooperatively contribute to inflammation. These results demonstrate that both IFN-γ and IL-17 have the potential to induce PGIA, but it is the strength of the IFN-γ response that regulates the contribution of each of these Th effector cytokines to disease.


  • Open Access

    CCR5 is involved in resolution of inflammation in proteoglycan‐induced arthritis

    by Paul D. Doodes, Yanxia Cao, Keith M. Hamel, Yumei Wang, Rachel L. Rodeghero, Tamas Kobezda, Alison Finnegan

    Objective: CCR5 and its ligands (CCL3, CCL4, and CCL5) may play a role in inflammatory cell recruitment into the joint. However, it was recently reported that CCR5 on T cells and neutrophils acts as a decoy receptor for CCL3 and CCL5 to assist in the resolution of inflammation. The aim of this study was to determine whether CCR5 functions as a proinflammatory or antiinflammatory mediator in arthritis, by examining the role of CCR5 in proteoglycan (PG)–induced arthritis (PGIA).Methods: Arthritis was induced by immunizing wild‐type (WT) and CCR5‐deficient (CCR5−/−) BALB/c mice with human PG in adjuvant. The onset and severity of PGIA were monitored over time. Met‐RANTES was used to block CCR5 in vivo. Arthritis was transferred to SCID mice, using spleen cells from arthritic WT and CCR5−/− mice. The expression of cytokines and chemokines was measured by enzyme‐linked immunosorbent assay.Results: In CCR5−/− mice and WT mice treated with the CCR5 inhibitor Met‐RANTES, exacerbated arthritis developed late in the disease course. The increase in arthritis severity in CCR5−/− mice correlated with elevated serum levels of CCL5. However, exacerbated arthritis was not intrinsic to the CCR5−/− lymphoid cells, because the arthritis that developed in SCID mouse recipients was similar to that in WT and CCR5−/− mice. CCR5 expression in the SCID mouse was sufficient to clear CCL5, because serum levels of CCL5 were the same in SCID mouse recipients receiving cells from either WT or CCR5−/− mice.Conclusion: These data demonstrate that CCR5 is a key player in controlling the resolution of inflammation in experimental arthritis.